Literature DB >> 18321816

The role of the NFkappaB signalling pathway in cancer.

María Cortés Sempere1, Vanesa Rodríguez Fanjul, Isabel Sánchez Pérez, Rosario Perona.   

Abstract

The nuclear factor kappa B (NFkappaB) signalling pathway regulates the expression of hundreds of genes that are involved in different cellular processes such as cell proliferation, survival, stress responses, cellular immunity and inflammation. Its aberrant regulation is involved in several pathologies, but its relevance in cellular transformation and cancer development has been extensively studied. Mutations in the core components of NFkappaB as well as in the cellular machinery that regulates its activation have been found in many types of tumours. On the other hand, its role in promoting cell survival is an important obstacle in many cancer therapies. The development of chemical inhibitors that block NFkappaB activation acting either directly on IKKs or on the proteosome machinery has shown antitumour and proapoptotic activity both in preclinical and clinical studies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18321816     DOI: 10.1007/s12094-008-0171-3

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  28 in total

1.  Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract.

Authors:  T F Barth; M Bentz; F Leithäuser; S Stilgenbauer; R Siebert; M Schlotter; R F Schlenk; H Döhner; P Möller
Journal:  Genes Chromosomes Cancer       Date:  2001-08       Impact factor: 5.006

2.  Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

Authors:  Lloyd T Lam; R Eric Davis; Jackie Pierce; Michael Hepperle; Yajun Xu; Maria Hottelet; Yuhua Nong; Danyi Wen; Julian Adams; Lenny Dang; Louis M Staudt
Journal:  Clin Cancer Res       Date:  2005-01-01       Impact factor: 12.531

3.  Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma.

Authors:  Noriko Fukuhara; Hiroyuki Tagawa; Yoshihiro Kameoka; Yumiko Kasugai; Sivasundaram Karnan; Junichi Kameoka; Takeshi Sasaki; Yasuo Morishima; Shigeo Nakamura; Masao Seto
Journal:  Cancer Sci       Date:  2006-06       Impact factor: 6.716

4.  Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.

Authors:  M Hinz; P Löser; S Mathas; D Krappmann; B Dörken; C Scheidereit
Journal:  Blood       Date:  2001-05-01       Impact factor: 22.113

5.  Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits.

Authors:  C H Yang; A M Gonzalez-Angulo; J M Reuben; D J Booser; L Pusztai; S Krishnamurthy; D Esseltine; J Stec; K R Broglio; R Islam; G N Hortobagyi; M Cristofanilli
Journal:  Ann Oncol       Date:  2006-01-10       Impact factor: 32.976

Review 6.  The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies.

Authors:  A Neri; N S Fracchiolla; A Migliazza; D Trecca; L Lombardi
Journal:  Leuk Lymphoma       Date:  1996-09

7.  The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study.

Authors:  Angela M Davies; Christopher Ruel; Primo N Lara; Derick H Lau; Paul H Gumerlock; Richard Bold; Stephen Shibata; Heinz-Josef Lenz; David P Schenkein; David R Gandara
Journal:  J Thorac Oncol       Date:  2008-01       Impact factor: 15.609

8.  Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study.

Authors:  Nancy B Davis; David A Taber; Rafat H Ansari; Christopher W Ryan; Christopher George; Everett E Vokes; Nicholas J Vogelzang; Walter M Stadler
Journal:  J Clin Oncol       Date:  2004-01-01       Impact factor: 44.544

9.  Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer.

Authors:  Pedro T Ramirez; Charles N Landen; Robert L Coleman; Michael R Milam; Charles Levenback; Taren A Johnston; David M Gershenson
Journal:  Gynecol Oncol       Date:  2007-10-01       Impact factor: 5.482

10.  Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.

Authors:  Christos N Papandreou; Danai D Daliani; Darrell Nix; Hong Yang; Timothy Madden; Xuemei Wang; Christine S Pien; Randall E Millikan; Shi-Ming Tu; Lance Pagliaro; Jeri Kim; Julian Adams; Peter Elliott; Dixie Esseltine; Alexandria Petrusich; Pauline Dieringer; Cherie Perez; Christopher J Logothetis
Journal:  J Clin Oncol       Date:  2004-06-01       Impact factor: 44.544

View more
  24 in total

1.  Tumor suppressor FOXO3 participates in the regulation of intestinal inflammation.

Authors:  Lobke Snoeks; Christopher R Weber; Kaarin Wasland; Jerrold R Turner; Charles Vainder; Wentao Qi; Suzana D Savkovic
Journal:  Lab Invest       Date:  2009-07-27       Impact factor: 5.662

2.  Interplay between 15-lipoxygenase-1 and metastasis-associated antigen 1 in the metastatic potential of colorectal cancer.

Authors:  S Tunçer; S Tunçay Çağatay; A G Keşküş; M Çolakoğlu; Ö Konu; S Banerjee
Journal:  Cell Prolif       Date:  2016-06-19       Impact factor: 6.831

3.  miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8.

Authors:  Nan Hu; Jianli Zhang; Wenjing Cui; Guangyao Kong; Shuai Zhang; Lin Yue; Xiao Bai; Zhao Zhang; Weiying Zhang; Xiaodong Zhang; Lihong Ye
Journal:  J Biol Chem       Date:  2011-02-22       Impact factor: 5.157

Review 4.  Aging and inflammation: etiological culprits of cancer.

Authors:  Aamir Ahmad; Sanjeev Banerjee; Zhiwei Wang; Dejuan Kong; Adhip P N Majumdar; Fazlul H Sarkar
Journal:  Curr Aging Sci       Date:  2009-12

5.  p16 Protein and gigaxonin are associated with the ubiquitination of NFκB in cisplatin-induced senescence of cancer cells.

Authors:  Mysore S Veena; Reason Wilken; Jun-Ying Zheng; Ankur Gholkar; Natarajan Venkatesan; Darshni Vira; Sameer Ahmed; Saroj K Basak; Clifton L Dalgard; Sandhiya Ravichandran; Raj K Batra; Noriyuki Kasahara; David Elashoff; Michael C Fishbein; Julian P Whitelegge; Jorge Z Torres; Marilene B Wang; Eri S Srivatsan
Journal:  J Biol Chem       Date:  2014-10-20       Impact factor: 5.157

Review 6.  Tumor necrosis factor-mediated cell death: to break or to burst, that's the question.

Authors:  Franky Van Herreweghe; Nele Festjens; Wim Declercq; Peter Vandenabeele
Journal:  Cell Mol Life Sci       Date:  2010-03-04       Impact factor: 9.261

7.  Inhibition of mammary tumor growth and metastases to bone and liver by dietary grape polyphenols.

Authors:  Linette Castillo-Pichardo; Michelle M Martínez-Montemayor; Joel E Martínez; Kristin M Wall; Luis A Cubano; Suranganie Dharmawardhane
Journal:  Clin Exp Metastasis       Date:  2009-03-18       Impact factor: 5.150

8.  Regulation of gene expression in hepatic cells by the mammalian Target of Rapamycin (mTOR).

Authors:  Rosa H Jimenez; Ju-Seog Lee; Mirko Francesconi; Gastone Castellani; Nicola Neretti; Jennifer A Sanders; John Sedivy; Philip A Gruppuso
Journal:  PLoS One       Date:  2010-02-05       Impact factor: 3.240

9.  When neighbourhood matters: tumour microenvironment.

Authors:  M Pérez-Moreno
Journal:  Clin Transl Oncol       Date:  2009-02       Impact factor: 3.405

10.  Mechanism of PP2A-mediated IKK beta dephosphorylation: a systems biological approach.

Authors:  Johannes Witt; Sandra Barisic; Eva Schumann; Frank Allgöwer; Oliver Sawodny; Thomas Sauter; Dagmar Kulms
Journal:  BMC Syst Biol       Date:  2009-07-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.